PSEUDOCELL

The World Health Organization (WHO) on Wednesday endorsed the first malaria vaccine ‘ Mosquirix’ , which could prevent the deaths of tens of thousands of children a year.  To have a malaria vaccine that is safe, moderately effective and ready for distribution is “a historic event,” said Dr. Pedro Alonso, director of the WHO global malaria program.   The new vaccine, even with modest efficacy, is considered as the best new development in the battle against malaria in decades, some experts said.  Studies show that malaria kills about half a million people each year, nearly all of them in sub-Saharan Africa — including 260,000 children under 5.  The new vaccine, made by GlaxoSmithKline, rouses a child’s immune system to beat Plasmodium falciparum, the deadliest of five malarial pathogens and the most of which are prevalent in Africa. Mosquirix is given in three doses between ages 5 and 17 months, and a fourth dose roughly 18 months later.   Clinical trials shows that the GlaxoSmithKline v

Multisystem Inflammatory Syndrome in children (MIS-C) is a serious condition that appears to be linked to COVID-19.   Many cases of MISC have been reported in Uttar Pradesh. MIS-C reported to develops a month after recovery from Covid.  MIS-C is rare, and most children who have it eventually get better with medical care. But some kids rapidly get worse, to the point where their lives are at risk.  Doctors and researchers are still researching why some children develop this illness after COVID-19 infection but not others  . What is MIS-C ? MIS-C is a serious condition in which organs such as heart, lungs, kidneys, brain, skin, eyes or gastrointestinal organs get inflamed.  MIS-C usually affects school-age children, most commonly 8 and 9 years old. MIS-C symptoms appear between two and six weeks (four weeks on average) after COVID-19 infection.  The exact reasons behind MIS-C is still unknown, but at present, most cases are associated with Covid. At times, the antibodies developed durin